Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luqi Fang (鹿芪方), also known as LuQi formula, is a Traditional Chinese Medicine (TCM) formula investigated for its therapeutic effects, particularly in cardiovascular conditions such as heart failure and myocardial fibrosis. Research indicates that Luqi Fang modulates the immune system by regulating macrophages and regulatory T cells, and inhibits inflammatory pathways including the NF-κB/CCL17 axis and NLRP3 inflammasome activation. Furthermore, it has been shown to influence cardiac remodeling by inhibiting endothelial-to-mesenchymal transition and activating the relaxin signaling pathway, affecting proteins like RXFP1, Smad2, and Smad3. These actions collectively contribute to its cardioprotective potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Luqi Fang.